Product Description: Navoximod (GDC-0919; NLG-?919) is a potent IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitor with Ki/EC50 of 7 nM/75 nM.
Applications: Cancer-programmed cell death
Formula: C18H21FN2O2
References: [1]Mario R. Mautino, et al. Abstract 491: NLG919, a novel indoleamine-2,3-dioxygenase (IDO)-pathway inhibitor drug candidate for cancer therapy. AACR 104th Annual Meeting 2013; Apr 6-10, 2013./[2]Li M, et al. The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma. J Immunother Cancer. 2014 Jul 7;2:21./[3]Chen Y, et al. An immunostimulatory dual-functional nanocarrier that improves cancer immunochemotherapy. Nat Commun. 2016 Nov 7;7:13443.
CAS Number: 1402837-78-8
Molecular Weight: 316.37
Compound Purity: 99.99
Research Area: Cancer
Solubility: DMSO : 100 mg/mL (ultrasonic)
Target: Indoleamine 2,3-Dioxygenase (IDO)
Deutsch
English
